About a week ago, FDA approved the very first treatment for patients with liver fibrosis caused by fatty liver disease.
Rezdiffra (resmetirom) is now approved for treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise.
While this is a significant milestone in the research area of NAFLD/NASH, many additional steps remain for all stakeholders in the field before establishing access to treatments for patients in Europe.
Quantify Research has several years of experience in conducting research on a globally unique NAFLD dataset, which is fit-for-purpose to support a broad range of strategic and scientific evidence gaps for multiple actors.
For more information, please visit our website! Here:
